Related Experiment Video
Updated: Feb 20, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.9K
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma
Sara A Byron1, Nhan L Tran2, Rebecca F Halperin3
1Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, Arizona.
Summary
Genomic profiling guides glioblastoma treatment. Next-generation sequencing successfully identified molecular targets, enabling timely, personalized therapy recommendations for recurrent glioblastoma patients.
Area of Science:
- Neuro-oncology
- Genomics
- Precision Medicine
Background:
- Glioblastoma is an aggressive brain cancer with limited treatment options.
- Molecular heterogeneity complicates treatment strategies.
- Recurrent glioblastoma presents significant therapeutic challenges.
Purpose of the Study:
- To assess the feasibility of using next-generation sequencing to guide treatment for recurrent glioblastoma.
- To determine if genomic profiling can yield actionable treatment recommendations within a clinical timeframe.
- To identify molecular targets for personalized therapy in recurrent glioblastoma.
Main Methods:
- Prospective feasibility trial involving adults with recurrent glioblastoma.
- Genome-wide exome and RNA sequencing of tumor tissue post-surgery.
- Multidisciplinary molecular tumor board review for treatment recommendations.
- Assessment of recommendation generation within 35 days of surgery.
Main Results:
- Genomic profiling and treatment recommendations were feasible within the 35-day timeframe for 94% of patients.
- Seven patients received treatments based on molecular profiling.
- Two patients achieved 12-month progression-free survival on recommended therapies.
- Analysis revealed actionable genomic alterations in matched tumor tissues.
Conclusions:
- Genome-wide molecular profiling is feasible for guiding glioblastoma treatment.
- Genomics-informed recommendations can be generated in real-time.
- This approach supports the development of central nervous system-penetrant, personalized therapies for recurrent glioblastoma.
